Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: A systematic review and meta-analysis based on randomized control trials
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: A systematic review and meta-analysis based on randomized control trials
Postoperative adjuvant cisplatin-based chemotherapy had been the standard care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer (NSCLC) for decades. However, the survival benefits were far from satisfactory in clinical practice.